Serological and molecular screening (HBV NAT-MP, HBsAg and anti-HBc) has been shown to be safe and reliable, allowing the detection of hepatitis B at different stages of the disease, including possible occult infections and HBV gene variants. This evidence concerns the gene KRT88P and hepatitis B virus infection.